NASDAQ · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · LARGE CAP
Exelixis, Inc. EXEL
17 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$2.3B
▲ 7.0% vs FY2024
EPS · FY25
$2.78
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
35.5%
Net margin · FY25
33.7%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 2.3B
Revenue, FY2025 · full 17-year series below
Revenue
Net income
34 cents of every revenue dollar became profit this year.
Per share
USD 2.78
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
35.5%
Return on equity, FY2025
ROE
Operating margin37.6%
Net margin33.7%
Return on assets27.0%
Each USD of equity produced 36 cents of profit this year.
Returned to shareholders
USD 947.5M
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacksUSD 947.5M
Share of profit121.1%
Consecutive raises—
USD 947.5M in buybacks — 121% of the year's profit, so the payout drew on cash built up earlier.
Growth
+18.6% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+12.9%
+18.6%
+51.2%
+18.4%
Net income
+62.5%
+47.6%
EPS, diluted
+70.6%
+51.4%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.26B
Shares outstanding, FY2025
Change, 5 years−15.8%
Change, 10 years+15.1%
The share count shrank 16% in five years — the same company, cut into fewer, larger slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 2.8B
total assets, end of FY2025
Total assetsUSD 2.8B
EquityUSD 2.2B
CashUSD 482.5M
Current ratio3.56×
Equity funds 76% of total assets.
History
17 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
Revenue $B
2.3
2.2
1.8
1.6
1.4
1.0
1.0
0.9
0.5
0.2
0.0
0.0
0.0
0.0
0.3
0.2
0.2
Operating income $B
0.9
0.6
0.2
0.2
0.3
0.1
0.4
0.4
0.2
−0.0
−0.1
−0.2
−0.2
−0.1
0.1
−0.1
−0.1
EBITDA $B
0.9
0.6
0.2
0.2
0.3
0.1
0.4
0.4
0.2
−0.0
−0.1
−0.2
−0.2
−0.1
0.1
−0.1
−0.1
Income tax $B
0.2
0.2
0.0
0.1
0.1
0.0
0.1
−0.2
0.0
0.0
0.0
−0.0
−0.0
0.0
0.0
−0.0
−0.0
Net income $B
0.8
0.5
0.2
0.2
0.2
0.1
0.3
0.7
0.2
−0.1
−0.2
−0.3
−0.2
−0.1
0.1
−0.1
−0.1
EPS, diluted $
2.78
1.76
0.65
0.56
0.72
0.35
1.02
2.21
0.49
−0.28
−0.77
−1.34
−1.29
−0.91
0.58
−0.85
−1.26
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
35.5
23.1
8.7
7.8
11.3
6.3
21.6
87.8
82.4
−78.6
·
·
·
·
·
·
·
Shares out B
0.26
0.28
0.30
0.32
0.32
0.31
0.30
0.30
0.30
0.29
0.23
0.20
0.18
0.18
0.14
0.11
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
49 of 49
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed